Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors (Q44824798)

6 December 2017

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors (English)

1 reference

6 December 2017

8

1 reference

Jacqueline Müller-Nordhorn

6 December 2017

Guido Rindi

9

0 references

3

object named as

Jacqueline Müller-Nordhorn

1 reference

6 December 2017

Ulrich-Frank Pape

1

1 reference

6 December 2017

Henning Jann

2

1 reference

6 December 2017

Angelina Bockelbrink

4

1 reference

6 December 2017

Uta Berndt

5

1 reference

6 December 2017

Stefan N Willich

6

1 reference

6 December 2017

Martin Koch

7

1 reference

6 December 2017

Bertram Wiedenmann

10

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

6 December 2017

1 reference

6 December 2017

113

1 reference

6 December 2017

256-265

1 reference

6 December 2017

2

1 reference

A 5-decade analysis of 13,715 carcinoid tumors

6 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Current status of gastrointestinal carcinoids

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Gastrointestinal carcinoids: characterization by site of origin and hormone production

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Carcinoids of the pancreas: an analysis of 156 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Population-based study of islet cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Endocrine tumours of the stomach.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

From the archives of the AFIP: Gastrointestinal carcinoids: imaging features with clinicopathologic comparison

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Carcinoid tumors of the duodenum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

The classification of carcinoid tum ours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.23549

1 reference

7 January 2021

Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: Why Such Guidelines and How We Went about It

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Well-differentiated gastric tumors/carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Gastrinoma (duodenal and pancreatic).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Well-differentiated pancreatic tumor/carcinoma: insulinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Rare functioning pancreatic endocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Well-differentiated pancreatic nonfunctioning tumors/carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Classification of low-grade neuroendocrine tumors of midgut and unknown origin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Rethinking TNM: breast cancer TNM classification for treatment decision-making and research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

The future of the TNM staging system in colorectal cancer: time for a debate?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23549

7 January 2021

Identifiers

DOI

10.1002/CNCR.23549

1 reference

6 December 2017

1 reference